Global Blood Therapeutics Inc (GBT) was Initiated by Wells Fargo to “Outperform”. Wells Fargo advised their investors in a research report released on Sep 30, 2016.
On the company’s financial health, Global Blood Therapeutics Inc reported $-0.58 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Aug 10, 2016. Analyst had a consensus of $-0.63.During the same quarter in the previous year, the company posted $-4.84 EPS.
In a different news, on Mar 14, 2016, Jung Choi (officer ) purchased 25,000 shares at $20.00 per share price. According to the SEC, on Jan 8, 2016, John Schembri (officer ) purchased 1,500 shares at $21.18 per share price. On Jan 7, 2016, Mark L Perry (director) purchased 5,000 shares at $20.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Global Blood Therapeutics Inc. is a biopharmaceutical company that engages in discovering developing and commercializing therapeutics to treat blood-based disorders. The Company is engaged in developing initial product candidate GBT440 oral prophylactic therapy for sickle cell disease (SCD). The Company offers randomized placebo-controlled double-blind single and multiple ascending dose Phase 1/2 clinical trial of GBT440 in healthy subjects and patients with SCD. It is also developing hemoglobin modifiers for pulmonary disorders such as acute respiratory distress syndrome in which increased oxygen delivery is needed. The Company through its GBT440 or analog also focuses on chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders and hereditary angioedema (HAE) which is in pre-clinical trials. In addition the Company develops TBD an oral kallikrein inhibitor which are in Phase 1/2 clinical trials.